- Home
- MBRX vs NERV Comparison
MBRX vs NERV Comparison
Compare MBRX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- NERV
- Stock Information
- Founded
- MBRX 2015
- NERV 2007
- Country
- MBRX United States
- NERV United States
- Employees
- MBRX N/A
- NERV N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- NERV Health Care
- Exchange
- MBRX Nasdaq
- NERV Nasdaq
- Market Cap
- MBRX 12.9M
- NERV 12.0M
- IPO Year
- MBRX 2016
- NERV 2014
- Fundamental
- Price
- MBRX $0.57
- NERV $2.13
- Analyst Decision
- MBRX Strong Buy
- NERV Hold
- Analyst Count
- MBRX 3
- NERV 1
- Target Price
- MBRX $5.33
- NERV $5.00
- AVG Volume (30 Days)
- MBRX 9.6M
- NERV 20.2K
- Earning Date
- MBRX 08-13-2025
- NERV 08-05-2025
- Dividend Yield
- MBRX N/A
- NERV N/A
- EPS Growth
- MBRX N/A
- NERV N/A
- EPS
- MBRX N/A
- NERV 0.83
- Revenue
- MBRX N/A
- NERV N/A
- Revenue This Year
- MBRX N/A
- NERV N/A
- Revenue Next Year
- MBRX N/A
- NERV N/A
- P/E Ratio
- MBRX N/A
- NERV $2.58
- Revenue Growth
- MBRX N/A
- NERV N/A
- 52 Week Low
- MBRX $0.25
- NERV $1.15
- 52 Week High
- MBRX $3.67
- NERV $3.30
- Technical
- Relative Strength Index (RSI)
- MBRX 45.87
- NERV 66.09
- Support Level
- MBRX $0.74
- NERV $1.94
- Resistance Level
- MBRX $0.96
- NERV $2.32
- Average True Range (ATR)
- MBRX 0.13
- NERV 0.15
- MACD
- MBRX 0.02
- NERV 0.03
- Stochastic Oscillator
- MBRX 25.85
- NERV 73.38
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.